Patents by Inventor David S. Snyder

David S. Snyder has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Pyrimido-pyrrolo-oxazine-dione compound inhibitors of the cystic fibrosis transmembrane conductance regulator protein and uses therefor
    Patent number: 9062073
    Abstract: Provided herein are benzopyrimido-pyrrolo-oxazine-dione (BPO) compounds and pyrimido-pyrrolo-quinoxalinedione (PPQ) compounds, and compositions comprising these compounds, that inhibit cystic fibrosis transmembrane conductance regulator (CFTR) mediated ion transport and that are useful for treating diseases and disorders associated with aberrantly increased CFTR chloride channel activity, such as polycystic kidney disease and secretory diarrheas. The compounds and compositions comprising the compounds described herein may be used for inhibiting expansion or preventing formation of cysts in persons who have polycystic kidney disease.
    Type: Grant
    Filed: May 25, 2012
    Date of Patent: June 23, 2015
    Assignee: The Regents of the University of California
    Inventors: Alan S. Verkman, David S. Snyder
  • PYRIMIDO-PYRROLO-OXAZINE-DIONE COMPOUND INHIBITORS OF THE CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR PROTEIN AND USES THEREFOR
    Publication number: 20140080821
    Abstract: Provided herein are benzopyrimido-pyrrolo-oxazine-dione (BPO) compounds and pyrimido-pyrrolo-quinoxalinedione (PPQ) compounds, and compositions comprising these compounds, that inhibit cystic fibrosis transmembrane conductance regulator (CFTR) mediated ion transport and that are useful for treating diseases and disorders associated with aberrantly increased CFTR chloride channel activity, such as polycystic kidney disease and secretory diarrheas. The compounds and compositions comprising the compounds described herein may be used for inhibiting expansion or preventing formation of cysts in persons who have polycystic kidney disease.
    Type: Application
    Filed: May 25, 2012
    Publication date: March 20, 2014
    Applicant: The Regents of the University of California
    Inventors: Alan S. Verkman, David S. Snyder
  • Orifice drain stop
    Patent number: 5709309
    Abstract: A sound attenuating drain stop for an orifice in an automotive floor pan has a resilient plug portion disposed in the orifice and a drainage bore extending axially therethrough, an annular groove for receiving the body panel so as to secure the plug portion thereto, and a compliant element completely obstructing the bore and selectively unobstructing cross-sectional areas of the bore in response to weight variation of fluid thereabove. The compliant element has a resilient, three-legged bridge member spanning the bore and deflectable under the weight of a first predetermined quantity of fluid to drain fluid above the element, and three pie-shaped flexible flaps defined by the bridge member and extending from an interior surface of the bore to the bridge member, the flexible flaps deflectable under the weight of a second predetermined quantity of water when the bridge member is undeflected.
    Type: Grant
    Filed: March 1, 1996
    Date of Patent: January 20, 1998
    Assignee: Ford Global Technologies, Inc.
    Inventors: Stephen W. Gallagher, David S. Snyder
  • Periodical display rack
    Patent number: D283272
    Type: Grant
    Filed: September 30, 1983
    Date of Patent: April 8, 1986
    Assignee: Gaylord Bros., Inc.
    Inventors: Gregory G. Mt. Pleasant, James R. Dokoupil, David S. Snyder
  • Paperback display rack
    Patent number: D283279
    Type: Grant
    Filed: September 30, 1983
    Date of Patent: April 8, 1986
    Assignee: Gaylord Bros., Inc.
    Inventors: Gregory G. Mt. Pleasant, James R. Dokoupil, David S. Snyder
  • Pyrimido-pyrrolo-oxazine-dione compound inhibitors of the cystic fibrosis transmembrane conductance regulator protein and uses therefor
    Patent number: RE48842
    Abstract: Provided herein are benzopyrimido-pyrrolo-oxazine-dione (BPO) compounds and pyrimido-pyrrolo-quinoxalinedione (PPQ) compounds, and compositions comprising these compounds, that inhibit cystic fibrosis transmembrane conductance regulator (CFTR) mediated ion transport and that are useful for treating diseases and disorders associated with aberrantly increased CFTR chloride channel activity, such as polycystic kidney disease and secretory diarrheas. The compounds and compositions comprising the compounds described herein may be used for inhibiting expansion or preventing formation of cysts in persons who have polycystic kidney disease.
    Type: Grant
    Filed: January 14, 2020
    Date of Patent: December 7, 2021
    Assignee: The Regents of the University of California
    Inventors: Alan S. Verkman, David S. Snyder